Ireland
--:--IST
Starting soon Not applicable

Exploring the Effects of Hand and Foot Exercise Intervention in Older Adults With Gynecological Cancer Receiving Chemotherapy Improvement of Peripheral Neuropathy and Quality of Life

NCT07362147 · tracked via the Priya Life Science Taiwan tracker
Phase
Not applicable
Started
2026-01-01
Last updated
2026-01-23

Condition(s) studied

Peripheral NeuropathyCervical CancerEndometrial CancerOvarian CancerVaginal CancersFallopian Tube Cancers

Investigational drug(s) / intervention(s)

hand and foot exercises

hand and foot exercises: The hand and foot exercise steps include hand and foot movements, practiced in a seated position. Hold each movement for ten seconds and then relax, repeating ten times. Perform the hand and foot exercises three times a day, for 10-15 minutes each time, three days a week, for twelve weeks.

Study summary

Paclitaxel-based drugs are commonly used adjuvant chemotherapy for gynecological cancer patients. Peripheral neuropathy, a side effect of this treatment, presents with symptoms such as numbness, tingling, decreased skin and reflex sensation, and impaired function in the hands and feet, thus affecting quality of life. Peripheral neuropathy is a side effect caused by the neurotoxicity of certain chemotherapeutic drugs, including paclitaxel and platinum-based drugs, resulting from the cumulative toxicity of specific drug doses. While numerous international studies have confirmed the preventative effects of hand and foot movement interventions, there is a lack of relevant literature in China. Therefore, this study aims to explore the effects of hand and foot movement interventions on elderly gynecological cancer patients undergoing chemotherapy.

Eligibility

Sex
FEMALE
Min age
65 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: Individuals aged 65 or older diagnosed with gynecological cancer (stage II to IV) by a physician, without skin or nail lesions. Individuals who have received at least one course of chemotherapy within the past year and have peripheral neuropathy, with chemotherapy drugs including paclitaxel (Paclitaxel or Docetaxel) or platinum-based drugs (Cisplatin or Carboplatin), and may receive combined targeted or immunotherapy. Individuals who are conscious and able to communicate in Mandarin, Taiwanese, or written language. Exclusion Criteria: Skin or nail lesions. Edema of 3+ or more in the extremities. History of diagnosis of diabetes, neuropathy, peripheral arterial ischemia, or multiple organ failure. Distal bone or skin metastases. Patients who have interrupted chemotherapy. Patients who have participated in similar studies.

Primary outcome measure(s)

  • Peripheral neuropathy — From enrollment to the end of treatment at 12 weeks.
    The content includes FACT/GOG-Ntx variable data.The maximum score is 120 points, and the minimum score is 0 points.A higher score indicates a better result.

Trial sites (1)

FacilityCityRegionStatus
Taipei Veterans General Hospital Taipei No.201, Sec. 2, Shipai Rd., Beitou District
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07362147 on ClinicalTrials.gov ↗ ← All trials in Taiwan